Update on PolarisDMD clinical trial

Muscular Dystrophy UK has today learned of the disappointing news about a phase 3 clinical trial of edasalonexent.

Edasalonexent was a potential treatment for preserving muscle function in patients with Duchenne muscular dystrophy. However, in the trial – PolarisDMD – it did not show effectiveness.

Sadly, this means that the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial, will be stopped.

Catabasis, the company that manufactures edasalonexent, has provided more information in a letter to the Duchenne community.


We are here for you. Please contact our helpline on 0800 652 6352 or email info@musculardystrophyuk.org if you have any queries or concerns about this news.